[ Back to EurekAlert! ] Public release date: 18-Dec-2007
[ | E-mail Share Share ]

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Link between chronic kidney disease and oxygen-deprived tissue

Implications for new approaches to kidney dialysis

PHILADELPHIA- Researchers at the University of Pennsylvania School of Medicine have discovered how low-oxygen conditions can worsen chronic kidney disease (CKD). The key player is a protein called hypoxia-inducible-factor (HIF-1) that, as its name suggests, is active when the kidney does not get enough oxygen, a condition known as hypoxia. The findings appear in a December issue of the Journal of Clinical Investigation.

CKD afflicts 20 million Americans who have hypertension, atherosclerosis, diabetes, and other conditions. The kidney has less oxygen reserves than other organs to start, and CKD is associated with less capillary blood flow, reducing oxygenation even further. As CKD progresses, kidneys become full of fibrous tissue and cannot filter wastes out of blood or regulate body salt. Eventually kidney dialysis, a form of renal replacement therapy, may be needed to carry out these processes. Ultimately, the clinical goal is to optimize treatment to halt or delay the progression of CKD by better understanding its molecular underpinnings.

"Fibrosis worsens when the kidney becomes hypoxic," states lead author Volker Haase, MD, Assistant Professor of Medicine, Renal Electrolyte and Hypertension Division. "We found that HIF-1 is more stable when oxygen is in short supply and that HIF-1 causes kidney epithelial cells to regress to a less-differentiated cell type. This transition is driven by HIF-1, a protein that turns on many genes that promote the synthesis of fibrous connective tissue, thus interfering with the kidney’s normal filtering function," says Haase.

The study was conducted using mice that had been engineered to turn off expression of HIF-1á (a critical subunit of HIF-1) in their kidneys. One kidney from each mouse was put under oxygen stress by obstructing the ureter, and the other kidney served as a control. As long as HIF-1a was silenced, fibrosis was reduced in the oxygen-deprived kidney. This demonstrated that HIF-1 promoted the fibrotic process under reduced oxygen conditions.

Kidney biopsies from patients with diabetes who also suffer from CKD were tested for HIF-1á levels. Normal kidneys had almost no HIF-1á, whereas kidneys from diabetics had moderate to high expression of HIF-1á. "This observation, along with increased expression of the genes controlled by HIF-1 in diseased kidneys in mice, shows that HIF-1 is the molecular link between hypoxia and CKD in humans as well as rodents," says Haase.

The next step is to test other models of CKD and identify additional molecular targets of HIF-1 that can promote fibrosis. “We also hope to study the inflammatory response to hypoxia in the diseased kidney,” concludes Haase. “We already know that some pro-inflammatory proteins are stimulated by hypoxia.”

Some day, it may be possible to use HIF-1 and HIF-regulated genes as molecular markers to identify those patients that are at high risk for rapid progression of CKD requiring dialysis.

###

This study was carried out by D. F. Higgins PhD, N. Shrimanker BA and Y. Akai, MD- PhD of the University of Pennsylvania; K. Kimura MD, Y. Akai MD, Y. Saito MD and M. Iwano MD of Nara Medical University, Japan; W. M. Bernhardt MD, B. Hohenstein MD and K-U. Eckardt MD of Friedrich-Alexander University, Germany; R. S. Johnson PhD of UCSD; M. Kretzler MD of University of Michigan; and C. D. Cohen MD of University of Munich, Germany. This research was supported by the National Institutes of Health, the University of Pennsylvania Research Foundation, the Penn Center for Molecular Studies in Digestive and Liver Disease, the Ministry of Education and Science of Japan, the American Heart Association and the Deutsche Forschungsgemeinschaft.

This release can be found at www.pennhealth.com/news.

PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is currently ranked #3 in the nation in U.S. News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals — its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s “Honor Roll” hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center — a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.